Intellia Therapeutics, Inc. (NASDAQ:NTLA) CEO John M. Leonard Sells 26,807 Shares

Intellia Therapeutics, Inc. (NASDAQ:NTLA) CEO John M. Leonard sold 26,807 shares of the firm’s stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the sale, the chief executive officer now directly owns 941,115 shares of the company’s stock, valued at $11,462,780.70. The trade was a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Intellia Therapeutics Stock Down 2.6 %

Shares of Intellia Therapeutics stock opened at $12.47 on Wednesday. Intellia Therapeutics, Inc. has a 52-week low of $11.34 and a 52-week high of $34.87. The company has a market capitalization of $1.27 billion, a P/E ratio of -2.29 and a beta of 1.83. The company has a 50 day moving average of $14.01 and a 200 day moving average of $19.28.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.37) by $0.03. The firm had revenue of $9.10 million for the quarter, compared to analysts’ expectations of $8.28 million. Intellia Therapeutics’s revenue for the quarter was down 24.1% on a year-over-year basis. During the same period last year, the firm posted ($1.38) earnings per share. As a group, research analysts anticipate that Intellia Therapeutics, Inc. will post -5.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

NTLA has been the topic of a number of research analyst reports. Barclays reduced their price target on shares of Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating on the stock in a research note on Friday, November 8th. Wells Fargo & Company cut their target price on Intellia Therapeutics from $80.00 to $70.00 and set an “overweight” rating on the stock in a research report on Monday, November 18th. Canaccord Genuity Group restated a “buy” rating and set a $90.00 price target on shares of Intellia Therapeutics in a research report on Tuesday, November 19th. William Blair reiterated a “neutral” rating and issued a $14.00 price objective on shares of Intellia Therapeutics in a report on Monday, November 18th. Finally, StockNews.com upgraded Intellia Therapeutics to a “sell” rating in a report on Friday, November 8th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $54.94.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. EverSource Wealth Advisors LLC raised its position in shares of Intellia Therapeutics by 763.5% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock worth $39,000 after acquiring an additional 1,550 shares in the last quarter. Eastern Bank acquired a new stake in Intellia Therapeutics during the third quarter worth approximately $41,000. Values First Advisors Inc. acquired a new stake in Intellia Therapeutics during the third quarter worth approximately $54,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Intellia Therapeutics by 27.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock worth $77,000 after buying an additional 794 shares during the last quarter. Finally, KBC Group NV boosted its holdings in shares of Intellia Therapeutics by 37.3% in the 3rd quarter. KBC Group NV now owns 3,753 shares of the company’s stock valued at $77,000 after buying an additional 1,020 shares in the last quarter. 88.77% of the stock is owned by institutional investors and hedge funds.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.